UBS O'Connor’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-258,084
Closed -$2.56M 466
2021
Q4
$2.56M Buy
258,084
+6,922
+3% +$68.8K 0.02% 452
2021
Q3
$2.48M Hold
251,162
0.02% 464
2021
Q2
$2.46M Sell
251,162
-348,424
-58% -$3.4M 0.02% 423
2021
Q1
$5.81M Buy
+599,586
New +$5.88M 0.08% 175

Other funds holding GRNA

UBS O'Connor's GRNA Position: Q1 2022 in Review

UBS O'Connor sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q1 2022, closing a stake of 258,084 shares — an estimated $2.56M sold.

UBS O'Connor first reported a position in GRNA in Q1 2021 and held it in 4 quarters. The position peaked at $5.81M in Q1 2021. 39 funds tracked by Wall St. Rank hold GRNA as of Q1 2022.

  • UBS O'Connor reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q1 2022 after selling out during the quarter.
  • UBS O'Connor sold 258,084 GreenLight Biosciences Holdings, PBC Common Stock shares in Q1 2022, an estimated $2.56M.
  • UBS O'Connor first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2021 and held it in 4 quarters.
  • UBS O'Connor's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $5.81M in Q1 2021.
  • 39 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q1 2022.

Based on UBS O'Connor's 13F filing for Q1 2022, filed 16 May 2022.